Recently, several studies supported the clinical response of anti-HER2 drugs in HER2-positive breast cancer, gastric adenocarcinoma, and gastroesophageal adenocarcinoma, which promotes the exploration of anti-HER2 agents in NSCLC. This evidence concerns the gene ERBB2 and gastric adenocarcinoma.